Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CEP 11981

X
Drug Profile

CEP 11981

Alternative Names: CEP-11981; ESK 981; SSR 106462

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon; sanofi-aventis
  • Developer Sanofi; Teva Pharmaceutical Industries
  • Class Antineoplastics; Carbazoles; Pyrimidines
  • Mechanism of Action TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 14 Aug 2023 University of Michigan Rogel Cancer Center plans phase-II trial for Adenocarcinoma, Gastrointestinal cancer and Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in October 2023 (PO) (NCT05988918),
  • 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer pharmacodynamics sections
  • 09 Nov 2007 Phase-I clinical trials in Solid tumours in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top